Here are 1-3 brief analogies for MaxCyte (MXCT):

• MaxCyte is like an Illumina for cell engineering, providing essential instruments and consumables that enable the discovery, development, and large-scale manufacturing of next-generation cell therapies.
• Think of MaxCyte as the "Intel Inside®" for cell therapies, providing the critical underlying technology (cell engineering platforms) that powers the development and production of advanced cell treatments by other companies.

MaxCyte's major products are:

• ExPERT ATx: A static electroporation instrument designed for small to medium scale cell transfection.
• ExPERT STx: A flow electroporation instrument used for protein production, drug development, and expression of therapeutic targets for cell-based assays.
• ExPERT GTx: A flow electroporation instrument for large scale transfection specifically in therapeutic applications.
• ExPERT VLx: An instrument tailored for very large volume cell-engineering processes.
• Disposable Processing Assemblies (PAs): Consumable components used to process and electroporate cells within their instrument systems.
• Accessories: Supplementary items including electroporation buffer solutions and software protocols that support the use of PAs and instruments.

MaxCyte, Inc. (MXCT) primarily sells its products and services to other companies in the life sciences, biotechnology, and pharmaceutical industries, rather than to individuals. These customers are typically developing cell therapies, engaging in drug discovery, or performing advanced biological research.

MaxCyte operates on a platform business model, licensing its proprietary ExPERT™ electroporation technology to therapeutic developers for use in their cell therapy programs. These licensing agreements, along with sales of instruments, disposable processing assemblies, and related accessories, form the basis of their customer relationships.

Some of MaxCyte's major customers and strategic partners include:

• CRISPR Therapeutics AG (Symbol: CRSP)
• Beam Therapeutics Inc. (Symbol: BEAM)
• Allogene Therapeutics, Inc. (Symbol: ALLO)
• Kite Pharma, Inc. (a subsidiary of Gilead Sciences, Inc.; Symbol: GILD)
• Novartis AG (Symbol: NVS)

Maher Masoud, President and Chief Executive Officer

Mr. Masoud was appointed President and Chief Executive Officer of MaxCyte in January 2024. He brings over 25 years of experience in the biopharmaceutical industry, including 17 years as an attorney and general counsel. Previously, he served as Executive Vice President, Head of Global Business Development, and Chief Counsel at MaxCyte. His biopharmaceutical career began as a research associate with Glen Research (a Maravai company), and he later served as Director and Corporate Counsel at Human Genome Sciences until its acquisition by GlaxoSmithKline. Prior to MaxCyte, Mr. Masoud oversaw the operations of six business subsidiaries at Wellstat, a life science holding company, and supported the launch of three FDA-approved therapies (Benlysta®, Vistogard® and Xuriden®) during his time at Human Genome Sciences and Wellstat.

Douglas Swirsky, Chief Financial Officer

Mr. Swirsky joined MaxCyte as Chief Financial Officer in March 2023. He is a seasoned financial leader with more than 20 years of experience in the healthcare sector, including executive roles at Nasdaq-listed organizations. Before MaxCyte, he was CFO and Treasurer of AavantiBio until its acquisition by Solid Biosciences, where he also served as interim President and a Director. Mr. Swirsky’s prior experience includes serving as President, CEO, and Director of Rexahn Pharmaceuticals (2018-2020) and President, CEO, and Director of GenVec (2013-2017) through its sale. He also held investment banking positions at firms such as Stifel Nicolaus, Morgan Stanley, UBS, PaineWebber, and Legg Mason. Mr. Swirsky currently serves as the Chairman of the Board of Cellectar Biosciences.

Ana-Paula Martins Fernandes, Senior Vice President, Commercial

Ms. Fernandes has expertise in building high-performing teams and developing go-to-market strategies, driving commercial growth through data-driven and eCommerce business models. She excels in strategic turnarounds, operational excellence, and customer-centric execution. Before joining MaxCyte, she held senior leadership roles at Azenta Life Sciences, Roche Diagnostics, Precision NanoSystems, Mettler-Toledo Rainin, and Life Technologies (Applied Biosystems/Thermo Fisher Scientific).

Patrick Horgan, Senior Vice President of Corporate Development

Mr. Horgan is an experienced corporate development and strategy leader with a career focused on supporting organizations in strategy development, mergers and acquisitions, strategic commercial and research collaborations, and other growth initiatives. He most recently held an operating role at CSafe Global. Prior to that, he held various corporate development and strategy roles at Sigma-Aldrich and its successor company, MilliporeSigma. Mr. Horgan began his career at PwC in audit and due diligence consulting.

Jeff Gelfman, Senior Vice President of Operations

Mr. Gelfman has over 25 years of diverse experience as a cross-functional finance, information technology, and operations leader, guiding numerous organizations through successful business transformations. Before this role, he was the Vice President of Finance at MaxCyte, and previously held leadership positions at Innate Pharma, AstraZeneca, MedImmune, and Accenture.

1. Reliance on the Success of Cell and Gene Therapy (CGT) Market and Strategic Platform License (SPL) Partners: MaxCyte's business model is deeply intertwined with the broader cell and gene therapy market's growth, funding, and regulatory successes. The company's revenue, particularly from its Strategic Platform Licenses (SPLs), is highly dependent on its partners' ability to successfully develop and commercialize their therapies. The timing and magnitude of SPL revenue are unpredictable and can be lumpy, with the value of an SPL agreement potentially going to zero if a partner's therapy fails in clinical trials. A shift in sentiment or funding away from ex-vivo cell/gene therapies could also significantly impact MaxCyte's prospects.

2. Challenges in Achieving Profitability and Managing Cash Burn: MaxCyte has faced persistent and widening net losses, alongside negative cash flow, as it continues to invest heavily in research and development and sales infrastructure. The company's financial health shows significant operational inefficiencies, with a negative operating margin and net margin. While MaxCyte has a robust balance sheet with substantial cash, concerns exist regarding its path to sustainable positive cash flow and achieving profitability before exhausting its cash reserves, especially if significant SPL revenues are delayed. MaxCyte has also experienced recent deceleration and declines in core revenue growth.

3. Intense Competition and Risk of Technological Obsolescence: MaxCyte operates in a competitive landscape with both large, well-resourced companies and emerging alternative cell engineering technologies. While its Flow Electroporation technology is a critical tool for the cell and gene therapy industry, the continuous evolution of biotechnology means that alternative or superior gene delivery methods could emerge, potentially eroding MaxCyte's market position.

MaxCyte (NASDAQ: MXCT) operates within the dynamic and rapidly expanding cell and gene therapy market, providing essential enabling technologies through its ExPERT™ platform, which utilizes Flow Electroporation® technology.

Addressable Markets for MaxCyte's Products and Services:

Global Cell and Gene Therapy Market:

The global cell and gene therapy market, which MaxCyte's technologies support, was estimated at approximately USD 26.35 billion in 2025 and is projected to reach around USD 146.31 billion by 2035, demonstrating a compound annual growth rate (CAGR) of 18.7% during this forecast period. Other estimates place the global market size at USD 27.02 billion in 2025, with a projection to grow to USD 232.22 billion by 2035, at a CAGR of 24%. Another source indicates the global market was valued at USD 8.94 billion in 2025 and is expected to grow to USD 45.24 billion by 2035, with a CAGR of 17.60%. Additionally, the market was estimated at USD 25.03 billion in 2025 and is projected to reach USD 117.46 billion by 2034, growing at a CAGR of 18.7% from 2025 to 2034.

Global Electroporation Instruments Market:

MaxCyte's ExPERT instruments are part of the broader electroporation instruments market. This global market was valued at USD 291.4 million in 2024 and is projected to reach USD 532.7 million by 2030, with a CAGR of 10.5%. Other data shows the global electroporation instruments market reaching US$ 251.42 million in 2024 and expected to reach US$ 374.04 million by 2033, growing at a CAGR of 4.5% from 2025 to 2033. Another estimate for the global electroporation instrument market size was USD 296.89 million in 2025 and is expected to reach USD 437.72 million by 2032, at a CAGR of 5.70%. A higher estimate places the global electroporation instruments market size at USD 974.92 million in 2024, projected to reach USD 1835.48 million by 2032, with a CAGR of 8.23% during the forecast period of 2025 to 2032.

Global Cell Therapy Technologies Market:

The cell therapy technologies market, which includes products like MaxCyte's instruments and consumables, is projected to reach USD 7.91 billion by 2030 from USD 4.41 billion in 2025, expanding at a CAGR of 12.4% from 2025 to 2030.

MaxCyte, Inc. (MXCT) is positioned for future revenue growth over the next 2-3 years, driven by several key factors stemming from its core cell engineering technology and strategic business model.

Here are the expected drivers of future revenue growth:

1. Expansion of Strategic Platform Licenses (SPLs) and Progression of Partnered Clinical Programs: MaxCyte's business model is significantly bolstered by its Strategic Platform Licenses (SPLs), which grant partners rights to use MaxCyte's Flow Electroporation technology for developing cell therapies. As more SPL agreements are signed, and existing partnered programs advance through clinical development and towards potential commercialization, MaxCyte expects to generate increased revenue from annual licensing fees, milestone payments, and sales-based royalties. The first commercial approval of a partner therapy (Casgevy) utilizing MaxCyte's technology provides validation for this revenue stream. The company has continued to add new SPL clients and supports a growing number of clinical programs.
2. Growth in Core Business Revenue from Instruments and Disposables: The demand for MaxCyte's ExPERT instruments and proprietary single-use disposable processing assemblies (PAs) is a fundamental driver of core revenue growth. As more partners and customers utilize MaxCyte's platforms for their cell engineering needs, the recurring revenue from PA sales and increasing utilization of instruments are anticipated to grow. Despite some cautious capital equipment spending in the broader market, MaxCyte has expressed optimism about improved growth in instrument sales.
3. Introduction and Adoption of New Products and Technologies: MaxCyte is expanding its product offerings, which is expected to contribute to top-line growth. The acquisition of SeQure Dx in January 2025 has broadened the company's capabilities into gene editing safety assessment, with revenue contributions anticipated to be weighted towards the latter half of 2025. Additionally, the launch of the ExPERT DTx™ in February 2026, a new high-throughput 96-well electroporation platform for research and drug discovery, is expected to accelerate discovery applications and add to overall revenue.
4. Increasing Number of Clinical Programs and Geographic Expansion: The growing number of active clinical trials across various therapeutic areas that leverage MaxCyte's platform directly translates to increased demand for its technology and enhances the potential for future milestone and royalty payments. MaxCyte's platform is supporting numerous active clinical trials, spanning genetic diseases, blood cancers, solid tumors, and autoimmune diseases. Furthermore, the company has specifically highlighted expectations for continued growth in the Asia Pacific region, indicating an outward focus on expanding its market presence geographically.

Share Issuance

• In July 2021, MaxCyte completed an upsized offering of 13,500,000 shares of common stock at an initial price of US$13.00 per share, generating anticipated gross proceeds of approximately US$175,500,000.
• During 2024, approximately 1.75 million shares were issued, increasing total shares outstanding to 105,711,093 as of December 31, 2024, from 103,961,670 at December 31, 2023.
• In January 2025, 19,904 shares of common stock were issued due to the exercise of share options and vesting of restricted stock units.

Inbound Investments

• As part of the July 2021 upsized offering, Casdin Partners Master Fund, L.P. expressed interest in purchasing 1,800,000 shares of common stock, which would represent approximately 14% of MaxCyte's outstanding shares post-offering.

Outbound Investments

• In January 2025, MaxCyte acquired SeQure Dx for an initial cash consideration of $4.5 million, with potential for up to an additional $2.5 million in contingent consideration. The total purchase, transaction, and one-time costs associated with the SeQure Dx acquisition contributed approximately $7.0 million to the decrease in cash, cash equivalents, and investments in early 2025. This acquisition aims to broaden MaxCyte's cell engineering offerings with on-target and off-target editing assessment services.

Capital Expenditures

• MaxCyte reported capital expenditures of $1.7 million for the full year 2024.
• In the third quarter of 2025, the company invested $300,000 in capital expenditures, primarily focused on funding long-term assets and infrastructure.
• MaxCyte is committed to ongoing investments in SeQure Dx, product enhancement initiatives, and expanding its cell engineering offerings.